China Approves Local Generics Of Glivec; Novartis Says Quality Doesn’t Come Close
This article was originally published in The Pink Sheet Daily
Novartis plans to draw on the safety profile of Glivec and a patient assistance program to ward off new competitors in China.
You may also be interested in...
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
By Celia Deng, Zhiyi Tong and Paul Zhang
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.